The national project IMODI, aims to develop new patient-derived tumor graft (PDX) models that will be used for speed up innovative therapeutic approach development. Well characterized PDX models that come from 9 types of human cancer represent a suitable tool for preclinical evaluation of novel therapeutic strategies in cancer.

It is now well established that, besides genetic features, one major host determinant in human health is the gut microbiota. These billions of microorganisms that colonize our gut contribute to human health but microbiota imbalance could be involved in cancer development. As one of the original partners in this consortium, Biofortis Mérieux Nutrisciences brings its experience in clinical trial management and its scientific knowledge in microbiota research.
The first objective is to coordinate the clinical study from 7 French clinical centers, for the recruitment of patients presenting several types of cancer: breast, ovary, liver and prostate. A stool and blood biobank associated with patient’s medical information will be generated, clinically characterized and standardized for biospecimen provider.
The second role is to explore the relationship between gut microbiota and cancer, and to identify the impact of pharmacological treatment on microbiota from patients and PDX models. This longitudinal microbiota study is realized before and after chemotherapy. The main objective is to identify “microbiota biomarkers” for cancer research.
This project will help in better understanding the microbiota statement in cancer initiation, cancer development and the response to several chemotherapy agents and to evaluate the efficacy of pharmacological treatment. This new approach should help to develop therapeutic approach to limit the side effect of chemotherapy.